Shares of plastic surgery solutions provider Sientra (NASDAQ:SIEN) are moving upward today after the U.S. Food and Drug Administration cleared its Portfinder technology offering.
The handheld device helps deliver a better experience in tissue expander filing sessions while also offering higher precision. Further, the 510(k) green signal for the technology will now help replace the traditional dangle magnet method and provide increased accuracy in port location.
Next, the company is looking at commercializing the product and further expanding its product portfolio which includes Sientra round and shaped breast implants, the AlloX2 breast tissue expander, Viality – a fat transfer system, and Biocorneum scar gel.
Despite today’s price gains, shares of the company are still down 17.2% so far this year.
Read full Disclosure
